Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherLiab,goodWill,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,totalCurrentAssets,netReceivables,longTermDebt,inventory,capitalSurplus,otherCurrentAssets,retainedEarnings,treasuryStock,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,longTermInvestments,shortTermInvestments,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,investments,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,exchange,marketState,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingAnnualDividendRate,trailingAnnualDividendYield,epsTrailingTwelveMonths,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,VIA.DE,-18647200000.0,1208659968,143600000,,-219100000,,-279200000,981600000,1506800000,381600000,381600000,,-167100000,,,,60100000,4577800000,4196200000,3071000000,-600700000,,-279200000,-279200000,27863700000.0,36777200000.0,21206900000.0,7948200000.0,57984100000.0,21206900000.0,5727600000.0,11990400000.0,6380200000.0,673900000.0,10132600000.0,2184400000.0,11749800000.0,4478700000.0,20917000000.0,4487600000.0,,,,,,,,,,,0.0,,,,,,,,,,,,,,,,1617200000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,12.224,1630579651,0.017999649,12.15,12.286,12.15,872,VIATRIS INC.  O.N.,GER,REGULAR,0.0051420853,0,False,False,0.14746557,12.15 - 12.286,12.206,12.22,12.34,finmb_290203,XETRA,Viatris Inc.,USD,2607,1005,1.4720001,0.13690478,10.752 - 17.57,-5.3459997,-0.30426863,10.752,17.57,1620649800,1620649800,1620649800,0.11,0.009011961,-1.871,2,17.72,12.096,0.12800026,0.010582033,12.161465,0.062535286,14818788352,0.689842,15,Europe/Berlin,CEST,7200000,1.48,,,17.57,10.75,12.1,12.16,2.61k,1k,1.21B,,1.21B,0.35%,78.51%,,,,,,0.37,2.97%,0.11,0.90%,,0.00%,,"Aug 23, 2021",,,"Dec 31, 2020","Jun 30, 2021",-13.12%,6.05%,1.34%,-12.42%,15.6B,16.48,67.60%,4.78B,4.85B,-2.05B,-1.87,,673.9M,0.56,23.1B,108.93,1.16,17.72,,,Value,15317,Healthcare,40000,9,8,"Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.",Canonsburg,724 514 1800,PA,7,1609372800,1625097600,5,United States,http://www.viatris.com,86400,9,1000 Mylan Boulevard,Drug Manufacturersâ€”Specialty & Generic
t-1,VIA.DE,-18982200000.0,1208659968,163000000,,-441300000,,-1037600000,968700000,1860700000,729000000,729000000,,-169000000,,,,596300000,4430300000,3701300000,2569600000,-1170300000,,-1037600000,-1037600000,28489600000.0,37564500000.0,21414700000.0,2941800000.0,58979200000.0,12100000.0,5267000000.0,11907300000.0,2671900000.0,806900000.0,9978100000.0,2255300000.0,12318500000.0,4529000000.0,22102200000.0,4942200000.0,18464600000.0,1695100000.0,4323600000.0,-1385600000.0,1997300000.0,-1385600000.0,3558300000.0,33600000.0,85400000.0,2043200000.0,191900000.0,236300000.0,-1063900000.0,-1099800000.0,-354600000.0,-36900000.0,-7800000.0,-22200000.0,848800000.0,1422500000.0,-203400000.0,-59800000.0,-28100000.0,395200000.0,-49500000.0,,2340400000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,12.224,1630579651,0.017999649,12.15,12.286,12.15,872,VIATRIS INC.  O.N.,GER,REGULAR,0.0051420853,0,False,False,0.14746557,12.15 - 12.286,12.206,12.22,12.34,finmb_290203,XETRA,Viatris Inc.,USD,2607,1005,1.4720001,0.13690478,10.752 - 17.57,-5.3459997,-0.30426863,10.752,17.57,1620649800,1620649800,1620649800,0.11,0.009011961,-1.871,2,17.72,12.096,0.12800026,0.010582033,12.161465,0.062535286,14818788352,0.689842,15,Europe/Berlin,CEST,7200000,1.48,,,17.57,10.75,12.1,12.16,2.61k,1k,1.21B,,1.21B,0.35%,78.51%,,,,,,0.37,2.97%,0.11,0.90%,,0.00%,,"Aug 23, 2021",,,"Dec 31, 2020","Jun 30, 2021",-13.12%,6.05%,1.34%,-12.42%,15.6B,16.48,67.60%,4.78B,4.85B,-2.05B,-1.87,,673.9M,0.56,23.1B,108.93,1.16,17.72,,,Value,15317,Healthcare,40000,9,8,"Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.",Canonsburg,724 514 1800,PA,7,1609372800,1625097600,5,United States,http://www.viatris.com,86400,9,1000 Mylan Boulevard,Drug Manufacturersâ€”Specialty & Generic
t-2,VIA.DE,-19076100000.0,1208659968,153300000,,-1013500000,,-915800000,1358700000,1361300000,-150700000,-150700000,,-144400000,,,,-97700000,3623500000,3774200000,2262200000,-862800000,,-915800000,-915800000,29683200000.0,38598900000.0,22954100000.0,2714800000.0,61553000000.0,12100000.0,5377300000.0,12347000000.0,2823900000.0,844400000.0,10562900000.0,2256300000.0,12867500000.0,4843800000.0,22429200000.0,5471900000.0,18438800000.0,1354700000.0,5361200000.0,-858000000.0,2147900000.0,-858000000.0,3783500000.0,47900000.0,84900000.0,1904200000.0,17000000.0,-22300000.0,154100000.0,149100000.0,-130200000.0,182900000.0,-800000.0,19800000.0,36200000.0,632500000.0,-209500000.0,106000000.0,-4200000.0,647800000.0,-116900000.0,-300000.0,2304600000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,12.224,1630579651,0.017999649,12.15,12.286,12.15,872,VIATRIS INC.  O.N.,GER,REGULAR,0.0051420853,0,False,False,0.14746557,12.15 - 12.286,12.206,12.22,12.34,finmb_290203,XETRA,Viatris Inc.,USD,2607,1005,1.4720001,0.13690478,10.752 - 17.57,-5.3459997,-0.30426863,10.752,17.57,1620649800,1620649800,1620649800,0.11,0.009011961,-1.871,2,17.72,12.096,0.12800026,0.010582033,12.161465,0.062535286,14818788352,0.689842,15,Europe/Berlin,CEST,7200000,1.48,,,17.57,10.75,12.1,12.16,2.61k,1k,1.21B,,1.21B,0.35%,78.51%,,,,,,0.37,2.97%,0.11,0.90%,,0.00%,,"Aug 23, 2021",,,"Dec 31, 2020","Jun 30, 2021",-13.12%,6.05%,1.34%,-12.42%,15.6B,16.48,67.60%,4.78B,4.85B,-2.05B,-1.87,,673.9M,0.56,23.1B,108.93,1.16,17.72,,,Value,15317,Healthcare,40000,9,8,"Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.",Canonsburg,724 514 1800,PA,7,1609372800,1625097600,5,United States,http://www.viatris.com,86400,9,1000 Mylan Boulevard,Drug Manufacturersâ€”Specialty & Generic
t-3,VIA.DE,-8235200000.0,1208659968,126000000,,241600000,,185700000,615200000,1260200000,519000000,519000000,,-117300000,,,,55900000,2972100000,2453100000,1711900000,-277400000,,185700000,185700000,10965800000.0,18695200000.0,12547900000.0,1078500000.0,31243100000.0,6100000.0,2161400000.0,9817300000.0,781500000.0,664500000.0,7275400000.0,3182600000.0,7334700000.0,2964100000.0,9101500000.0,3022000000.0,8688300000.0,415000000.0,6277000000.0,-2423500000.0,658100000.0,-1423800000.0,2286200000.0,57600000.0,80000000.0,1447800000.0,134800000.0,-58700000.0,400000.0,-145700000.0,131600000.0,342400000.0,-800000.0,21800000.0,525000000.0,432300000.0,-256600000.0,-149900000.0,-146100000.0,-18800000.0,-38200000.0,-400000.0,59300000.0,en-US,US,EQUITY,False,Delayed Quote,EUR,de_market,12.224,1630579651,0.017999649,12.15,12.286,12.15,872,VIATRIS INC.  O.N.,GER,REGULAR,0.0051420853,0,False,False,0.14746557,12.15 - 12.286,12.206,12.22,12.34,finmb_290203,XETRA,Viatris Inc.,USD,2607,1005,1.4720001,0.13690478,10.752 - 17.57,-5.3459997,-0.30426863,10.752,17.57,1620649800,1620649800,1620649800,0.11,0.009011961,-1.871,2,17.72,12.096,0.12800026,0.010582033,12.161465,0.062535286,14818788352,0.689842,15,Europe/Berlin,CEST,7200000,1.48,,,17.57,10.75,12.1,12.16,2.61k,1k,1.21B,,1.21B,0.35%,78.51%,,,,,,0.37,2.97%,0.11,0.90%,,0.00%,,"Aug 23, 2021",,,"Dec 31, 2020","Jun 30, 2021",-13.12%,6.05%,1.34%,-12.42%,15.6B,16.48,67.60%,4.78B,4.85B,-2.05B,-1.87,,673.9M,0.56,23.1B,108.93,1.16,17.72,,,Value,15317,Healthcare,40000,9,8,"Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania.",Canonsburg,724 514 1800,PA,7,1609372800,1625097600,5,United States,http://www.viatris.com,86400,9,1000 Mylan Boulevard,Drug Manufacturersâ€”Specialty & Generic
